First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach
3
Issued Date
2026-02-01
Resource Type
ISSN
21461414
eISSN
21471959
Scopus ID
2-s2.0-105029260789
Journal Title
Molecular Imaging and Radionuclide Therapy
Volume
35
Issue
1
Start Page
78
End Page
83
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecular Imaging and Radionuclide Therapy Vol.35 No.1 (2026) , 78-83
Suggested Citation
Amnuaywattakorn S., Charoenphun P., Ativitavas T., Pasawang P., Khamwan K., Thongpraparn T., Khiewvan B., Ruangma P., Chamroonrat W., Chuamsaamarkkee K. First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach. Molecular Imaging and Radionuclide Therapy Vol.35 No.1 (2026) , 78-83. 83. doi:10.4274/mirt.galenos.2026.28863 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114996
Title
First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach
Corresponding Author(s)
Other Contributor(s)
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has become an established treatment option for metastatic castration-resistant prostate cancer. Although lutetium-177 (<sup>177</sup>Lu) PSMA therapy has shown promising clinical benefits, terbium-161 (<sup>161</sup>Tb) PSMA is an emerging theranostic agent offering potential advantages due to its combination of beta and Auger electron emissions. This work presents the first documented case in Thailand and Southeast Asia of a patient treated at Ramathibodi Hospital with <sup>161</sup>Tb-PSMA following progression on <sup>177</sup>Lu-PSMA therapy. This report describes the clinical application of this novel radiopharmaceutical, the implementation of quantitative imaging protocols, single photon emission computed tomography/computed tomography calibration processes, and absorbed dose estimations from voxel-based dosimetry that contributed to individualised treatment planning.